<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113461</url>
  </required_header>
  <id_info>
    <org_study_id>PD10057866</org_study_id>
    <secondary_id>R01AG054435</secondary_id>
    <nct_id>NCT03113461</nct_id>
  </id_info>
  <brief_title>MCI: CPAP Treatment of OSA (Memories2)</brief_title>
  <acronym>MCI:OSA</acronym>
  <official_title>Changing the Trajectory of Mild Cognitive Impairment With CPAP Treatment of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine whether obstructive sleep apnea (OSA) treatment&#xD;
      with positive airway pressure therapy (CPAP) can delay the progression of cognitive&#xD;
      impairment in patients with amnestic Mild Cognitive Impairment (MCI) as measured by cognitive&#xD;
      testing, and brain magnetic resonance imaging (MRI) scans. Study participants will be&#xD;
      assessed at baseline, six-month (cognitive tests only) and one-year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A growing number of research studies suggest that obstructive sleep apnea (OSA),&#xD;
      characterized by episodic nocturnal collapse of the upper airway and reduction/cessation of&#xD;
      breathing leading to significant nocturnal hypoxia, is associated with an increased risk of&#xD;
      cognitive impairment. OSA is effectively treated with continuous positive airway pressure&#xD;
      (CPAP), a pressurized nasal/face mask worn during sleep, but health care providers do not&#xD;
      often prescribe it for Mild Cognitive Impairment (MCI) because there are no large,&#xD;
      prospective research studies in this population confirming efficacy.&#xD;
&#xD;
      This multi-site study will have a sample size of n=460 divided into three groups followed for&#xD;
      one year: 1) a CPAP adherent group (approximately n=200); 2) two control groups consisting of&#xD;
      2a) a CPAP non-adherent control group (approximately n=160) and 2b) a no apnea control group&#xD;
      (n=100). This will allow us to confirm whether CPAP treatment, controlling for risk factors&#xD;
      such as neuroimaging findings and OSA severity at baseline, predicts the primary outcome of&#xD;
      cognitive function at 1-year follow-up. Study participants will also undergo an Amyloid PET&#xD;
      scan, use wearable activity monitors and functional/structural MRI brain scans.&#xD;
&#xD;
      This research study will thus examine the one year effects of CPAP on cognitive function and&#xD;
      elucidate physiological mechanisms for cognitive decline in aMCI and OSA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>CPAP intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digit Symbol-Coding test</measure>
    <time_frame>one-year follow-up</time_frame>
    <description>incorporates both elements of memory and processing speed and correlates with executive functioning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating Scale</measure>
    <time_frame>one-year follow-up</time_frame>
    <description>Assessment of global cognition</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>CPAP adherent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants in this arm are using the CPAP intervention consistently</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP non-adherent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants in this arm are not using the CPAP intervention consistently</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No OSA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study participants who do not have OSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>non-invasive positive airway pressure applied using an oronasal mask</description>
    <arm_group_label>CPAP adherent</arm_group_label>
    <arm_group_label>CPAP non-adherent</arm_group_label>
    <other_name>continuous positive airway pressure therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 55-85 years;&#xD;
&#xD;
          2. moderate to severe OSA as defined by an AHI â‰¥ 15 events/hr, or no apnea defined by an&#xD;
             AHI&lt;5 events/hr using American Academy of Sleep Medicine (AASM) diagnostic methodology&#xD;
             as determined on a diagnostic polysomnography;&#xD;
&#xD;
          3. Scoring education adjusted scores 28-35 (inclusive) on optional Telephone Interview&#xD;
             for Cognitive Status Modified (pre-screen);&#xD;
&#xD;
          4. Scoring 0-0.5 on the Clinical Dementia Rating Scale (CDR);&#xD;
&#xD;
          5. Scoring 23-30 on the Mini Mental State Examination (MMSE) (exceptions may be made for&#xD;
             participants with &lt;8 years of education as determined by the clinical research team);&#xD;
&#xD;
          6. Memory impairment approximately 1.0-1.5 standard deviations below normal (adjusted for&#xD;
             age and education) determined by scores on the Logical Memory II a test from the&#xD;
             Wechsler memory scale;&#xD;
&#xD;
          7. permitted medications (antidepressants, etc.) stable for at least 4 weeks (12 weeks&#xD;
             for cholinesterase inhibitors/memantine) as per ADNI3 criteria;&#xD;
&#xD;
          8. Non-depressed: Scoring &lt; 6 on the Geriatric Depression Scale;&#xD;
&#xD;
          9. study partner, defined as an informant/caregiver who will be able to answer questions&#xD;
             about the study participant, and meets one of the following criteria: (a) lives with&#xD;
             the participant; (b) spends at least 3 times per week in-person contact with the&#xD;
             participant; (c) spends at least 3 times per week in phone contact with the&#xD;
             participant; or (d) spends at least 10 hours per week in any combination of phone or&#xD;
             in person contact;&#xD;
&#xD;
         10. adequate visual and auditory acuity to allow testing;&#xD;
&#xD;
         11. Post-menopause or surgically sterile;&#xD;
&#xD;
         12. testability - willing and able to complete baseline, 6-month, and 1-year outcome&#xD;
             measures, and willing to send in the CPAP Smartcard for adherence;&#xD;
&#xD;
         13. completed at least 6 grades of education; and&#xD;
&#xD;
         14. fluent in English or Spanish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. any significant neurologic disease other than aMCI, such as Parkinson's Disease,&#xD;
             Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy,&#xD;
             multiple sclerosis, head trauma followed by permanent neurologic deficits or known&#xD;
             congenital brain structure abnormalities; within the past 6 months brain tumor, or&#xD;
             seizure disorder, or subdural hematoma, or post-stroke (based on Modified Hachinski&#xD;
             Ischemic Score);&#xD;
&#xD;
          2. Optional: MRI exclusions - presence of pacemakers, aneurysm clips, artificial heart&#xD;
             valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body;&#xD;
             however, the participant has the option of participating in the study without having&#xD;
             an MRI;&#xD;
&#xD;
          3. psychiatric disorders, including uncontrolled major depression, newly diagnosed or&#xD;
             exacerbation in past 6 months of bipolar disorder as described in the DSM-IV,&#xD;
             psychotic features, agitation or behavioral problems within the past 6 months that&#xD;
             could lead to difficulty complying with the protocol, or history of schizophrenia&#xD;
             (DSM-IV criteria);&#xD;
&#xD;
          4. history of alcohol abuse or dependence within the past 6 months (DSM-IV criteria);&#xD;
&#xD;
          5. any current significant systemic illness or unstable medical condition that could lead&#xD;
             to difficulty in complying with the protocol (such as unstable cardiovascular&#xD;
             disease); current use of supplemental oxygen or hypoxemia indicated by documented&#xD;
             daytime oxyhemoglobin saturation &lt;90% on room air, uncontrolled thyroid disease (to be&#xD;
             included must be on stable dose of thyroid medication for &gt;6 months), uncontrolled&#xD;
             cirrhosis, cancer diagnosis within the past 6 months (exceptions may be made at the&#xD;
             PI's discretion depending on cancer severity and the treatment required), clinically&#xD;
             significant laboratory abnormalities such as reported untreated folate, B12, or TSH&#xD;
             disease, or resident of a skilled nursing facility;&#xD;
&#xD;
          6. participation in clinical studies involving neuropsychological measures being&#xD;
             conducted more than twice a year;&#xD;
&#xD;
          7. received and was adherent to CPAP or bi-level pressure for OSA within the past 6&#xD;
             months;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nalaka Gooneratne, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Richards, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Wolk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Morris, MS</last_name>
    <phone>(215)-573-7293</phone>
    <email>jennifer.morris3@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130-4862</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandye Mazdra</last_name>
      <phone>314-566-7038</phone>
      <email>bmazdra@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Luqi Chi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Nathanson</last_name>
      <phone>215-746-7465</phone>
      <email>nathansa@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Nalaka Gooneratne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Rangel</last_name>
      <phone>512-471-9462</phone>
      <email>arangel@nursing.utexas.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eddy Vass</last_name>
      <phone>512-471-9462</phone>
      <email>eddy.vass@nursing.utexas.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathy Richards, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Webber</last_name>
      <email>cmn6x@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Davis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Quigg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Barrett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive impairment</keyword>
  <keyword>sleep apnea</keyword>
  <keyword>positive airway pressure therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Pending</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

